Hexaminolevulinate
This prodrug is used as a photosensitizing agent to improve the detection of bladder cancer during cystoscopy. After being instilled into the bladder, it is absorbed by cancer cells and converted to fluorescent compounds, causing them to glow pink-red under blue-violet light while normal tissue appears blue. This technique helps doctors visualize and biopsy suspicious lesions more accurately.
Masse moléculaire
215,2900 g/mol
LogP
1,10
TPSA
69,40 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCCCCCOC(=O)CCC(=O)CN
InChI
InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3
Molecular Formula
C11H21NO3
HBD / HBA
1 / 4
Liaisons Rotatives
10
Atomes Lourds
15
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
This prodrug is used as a photosensitizing agent to improve the detection of bladder cancer during cystoscopy. After being instilled into the bladder, it is absorbed by cancer cells and converted to fluorescent compounds, causing them to glow pink-red under blue-violet light while normal tissue appears blue. This technique helps doctors visualize and biopsy suspicious lesions more accurately.
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Yes, Hexaminolevulinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201784. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6433083. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hexaminolevulinate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hexaminolevulinate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hexaminolevulinate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hexaminolevulinate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hexaminolevulinate"></drugfyi-drug>